Ads
related to: how long will myeloma last- Treatment Process
Discover The Treatment Info
& View Availability Here.
- Efficacy Data
Review Efficacy, Safety, & Clinical
Trial Data On The HCP Site.
- Treatment Centers
This RRMM Option Is Available
At Certified Treatment Centers.
- Important Safety Info
HCPs: Review Important Safety Info
For This Option In Clinical Trials.
- Patient Eligibility
Discover If This RRMM Treatment
Option Is Right For Your Patients.
- Nurse Support
Nurses: View The Treatment Journey,
Safety Info, Resources & FAQs Here.
- Treatment Process
Search results
Results From The WOW.Com Content Network
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. [6] Often, no symptoms are noticed initially. [10] As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. [10]
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone. [8] It is taken by mouth. [8]
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
The FDA approved carfilzomib in July 2012, for use in people with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomide) and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Around 35,000 multiple myeloma cases are reported each year in the U.S. Older adults, men and people with obesity have a higher risk of the disease, though doctors are still trying to understand ...
Multiple myeloma cells with higher levels of CD38 show greater daratumumab-mediated cell lysis than cells with low CD38 expression. [28] CD38 enzyme results in the formation of the immunosuppressive substance adenosine , so eliminating CD38-containing cells increases the ability of the immune system to eliminate cancer.
Ad
related to: how long will myeloma last